Literature DB >> 17560302

Immunopathogenesis of sarcoidosis.

Aliya Noor1, Kenneth S Knox.   

Abstract

The immunopathogenesis of sarcoidosis has been difficult to charaterize given the heterogeneity of disease, the elusiveness of the causative antigen, and the lack of an adequate animal model. However, by examining well-defined clinical cohorts, the interplay between genetic predisposition and immunologic response has been increasingly informative. Technological advances in cellular analysis have allowed researchers to characterize the immune responses important in the maintenance of granulomatous inflammation. Finally, "new" clinical observations such as granuloma responsiveness to targeted biological therapies, sarcoid developing during immune restoration, and the relationship between sarcoidosis and Hepatitis C will provide future insight to the immunopathogenesis of sarcoidosis.

Entities:  

Mesh:

Year:  2007        PMID: 17560302     DOI: 10.1016/j.clindermatol.2007.03.002

Source DB:  PubMed          Journal:  Clin Dermatol        ISSN: 0738-081X            Impact factor:   3.541


  20 in total

1.  Early prediction of sarcoidosis prognosis with HLA typing: a 5 year follow-up study.

Authors:  Ezgi Ozyilmaz; Ozlem Goruroglu Ozturk; Ali Durmaz; Orhan Othman Hasan; Bugra Guzelbaba; Gulsah Seydaoglu; Sedat Kuleci; Ismail Hanta; Eren Erken; Ali Kocabas
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

Review 2.  Potential immunotherapies for sarcoidosis.

Authors:  Van Le; Elliott D Crouser
Journal:  Expert Opin Biol Ther       Date:  2018-01-17       Impact factor: 4.388

Review 3.  Update on Treatment in Cardiac Sarcoidosis.

Authors:  Laura Young; Brett W Sperry; Rory Hachamovitch
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-06

Review 4.  The potential of the immunological markers of sarcoidosis in exhaled breath and peripheral blood as future diagnostic and monitoring techniques.

Authors:  Hasib Ahmadzai; Denis Wakefield; Paul S Thomas
Journal:  Inflammopharmacology       Date:  2011-02-13       Impact factor: 4.473

Review 5.  Sarcoidosis: a Critical Review of History and Milestones.

Authors:  Paolo Spagnolo
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

Review 6.  Sarcoidosis and molecular mimicry--important etiopathogenetic aspects: current state and future directions.

Authors:  Georgi Tchernev; Julian Ananiev; José Carlos Cardoso; Uwe Wollina; Shyam B Verma; James W Patterson; Lyubomir A Dourmishev; Michael Tronnier; Hiroyuki Okamoto; Kana Mizuno; Nobuo Kanazawa; Maya Gulubova; Irena Manolova; Cristina Salaro
Journal:  Wien Klin Wochenschr       Date:  2012-04-14       Impact factor: 1.704

7.  Significant CD4, CD8, and CD19 lymphopenia in peripheral blood of sarcoidosis patients correlates with severe disease manifestations.

Authors:  Nadera J Sweiss; Rafah Salloum; Seema Gandhi; Seema Ghandi; Maria-Luisa Alegre; Ray Sawaqed; Maria Badaracco; Kenneth Pursell; David Pitrak; Robert P Baughman; David R Moller; Joe G N Garcia; Timothy B Niewold
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

8.  ApoE-deficient mice on cholate-containing high-fat diet reveal a pathology similar to lung sarcoidosis.

Authors:  Andriy O Samokhin; Frank Bühling; Franz Theissig; Dieter Brömme
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

9.  Altered Cyclooxygenase-2 Expression in Pulmonary Sarcoidosis is not Related to Clinical Classifications.

Authors:  Justyna Kiszałkiewicz; Wojciech J Piotrowski; Dorota Pastuszak-Lewandoska; Paweł Górski; Adam Antczak; Witold Górski; Daria Domańska-Senderowska; Monika Migdalska-Sęk; Karolina H Czarnecka; Ewa Nawrot; Ewa Brzeziańska-Lasota
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

10.  Protein levels of CC chemokine ligand (CCL)15, CCL16 and macrophage stimulating protein in patients with sarcoidosis.

Authors:  A Arakelyan; E Kriegova; Z Kubistova; F Mrazek; M Kverka; R M du Bois; V Kolek; M Petrek
Journal:  Clin Exp Immunol       Date:  2009-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.